Wyeth seeks approvals of two postmenopausal drugs

NEW YORK, June 26 (Reuters) Wyeth today said it has asked Us regulators to approve two new prescription drugs for postmenopausal women, one to prevent osteoporosis and the other to treat moderate to severe symptoms of menopause.

The Madison, New Jersey-based drugmaker said it had asked the US Food and Drug Administration to approve bazedoxifene -- a member of the selective estrogen receptor modulator (SERM) class of drugs -- to prevent postmenopausal osteoporosis.

It said it also asked the FDA to approve desvenlafaxine succinate, a non-hormonal drug to treat vasomotor symptoms of menopause, such as hot flashes and night sweats.

REUTERS SB RS2127